Biotech News

Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process

Seer, Inc (SEER)Seer, IncCompany update

REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors (the “Special Committee”) has concluded its review process and decided to

Related news

Seer, Inc

Deep Proteomics Company Seer develops tools for large-scale, unbiased analysis of the proteome across research, translational medicine, and drug development. Proteograph Product Suite The Proteograph platform combines engineered nanoparticles, automated sample processing, consumables, and analytical software to capture proteins across a...

Recent company news

Stock data

Close
1.39 USD
Market cap
102.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States